Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | IMUX | Stock Option | Disposed to Issuer | -65K | -100% | 0 | Mar 4, 2024 | Common Stock | 65K | $13.29 | Direct | F1 | ||
transaction | IMUX | Stock Option | Disposed to Issuer | -80K | -100% | 0 | Mar 4, 2024 | Common Stock | 80K | $12.30 | Direct | F1 | ||
transaction | IMUX | Stock Option | Disposed to Issuer | -115K | -100% | 0 | Mar 4, 2024 | Common Stock | 115K | $15.72 | Direct | F1 | ||
transaction | IMUX | Stock Option | Disposed to Issuer | -215K | -100% | 0 | Mar 4, 2024 | Common Stock | 215K | $10.73 | Direct | F1 | ||
transaction | IMUX | Stock Option | Disposed to Issuer | -10K | -100% | 0 | Mar 4, 2024 | Common Stock | 10K | $3.40 | Direct | F1 | ||
transaction | IMUX | Stock Option | Award | +485K | 485K | Mar 4, 2024 | Common Stock | 485K | $1.72 | Direct | F1 |
Id | Content |
---|---|
F1 | On March 4, 2024, the stockholders of Immunic, Inc. approved a proposal to reduce the exercise price of all employee stock options having an exercise price above $3.00 per share (the "Eligible Options") to the greater of $1.72 and 110% of the closing price on a future repricing date to be set by the Board of Directors. The Board of Directors then determined that the exercise price of all Eligible Options will be repriced to $1.72 per share, which is greater than 110% of the closing price of the Common Stock on March 4, 2024, the repricing date set by the Board of Directors. Accordingly, this Form 4 reflects the cancellation of each Eligible Option and the reissuance of all Eligible Options at an exercise price of $1.72 per share. Following the repricing, each Eligible Option retains its respective original vesting schedule and expiration date. |